From the molecular standpoint, FLs almost universally harbor t(14;18) translocations involving fusion of BCL2 to regulatory elements associated with immunoglobulin heavy chain locus (2) . Constitutive expression of BCL2 suppresses apoptosis, which would otherwise occur physiologically in GC B-cells.
Mice engineered to express BCL2 under the control of the VAV2 promoter develop a FL-like disease, albeit with a long latency period (3) . BCL2 is a direct transcriptional target of BCL6, which causes its expression to be completely silenced during the GC reaction. Translocation of BCL2 enables its escape from BCL6 repression. This leads to a situation where both proteins BCL2 and BCL6 are expressed together. Along these lines, it has been reported that >90% of FL cases express BCL6 (4, 5) . The implication of BCL6 expression in FL has not been explored.
In normal GC B-cells the most established function of BCL6 is to repress critical checkpoint and DNA damage repair pathway genes including ATR, CHEK1, TP53, CDKN1A, etc. Through this mechanism GC B-cells can proliferate and tolerate the DNA damage associated with somatic hypermutation and class switch recombination (6) . The survival and growth checkpoint functions of BCL6 are also maintained in diffuse large B-cell lymphomas (DLBCLs), which like FL derive from GC B-cells. BCL6
expression in DLBCL is maintained in part through chromosomal translocations, although most DLBCLs express BCL6 regardless of genetic lesions. Functional assays demonstrate that DLBCL cells are dependent on BCL6 regardless of translocations (6) . Hence BCL6 more than an oncogene is
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Author Manuscript Published OnlineFirst on February 23, 2017; DOI: 10.1158/2159-8290.CD- actually a lineage factor for DLBCL. BCL6 is a member of the BTB-POZ family of transcription factors, and mediates transcriptional repression in large part by recruiting the SMRT, NCoR and BCoR corepressors via the BTB domain (6) . Specific peptidomimetic inhibitors of the BCL6 BTB domain kill DLBCL cells in vitro and in vivo (7) (8) (9) .
Traditionally BCL6 has not been considered as a phenotypic driver in FL, since these tumors, particularly the low grade ones only rarely display BCL6 translocations in their early stages, and have an indolent phenotype. However, the potent oncogenic functions of BCL6 make it unlikely that its constitutive expression in FL is merely a passenger marker. BCL6 biological functions are dependent on the target genes that it regulates. The biological functions of BCL6 are not likely limited to repressing cell growth and DNA damage checkpoints. It is entirely possible that other sets of target genes might be crucial for putative roles of BCL6 in FL. Indeed previous work showed that BCL6 may function through partially different target genes in DLBCL as compared to normal GC B-cells (10) .
Based on these considerations we hypothesized that BCL6 might also function as an oncoprotein in FL and that any such role would be linked to repression of specific sets of target genes. Discovery of BCL6 target genes in FL seemed like an appropriate starting point to address these questions.
Through this approach we report a novel function for BCL6 in binding and repressing expression and activity of NOTCH2 in FL cells. Repression of NOTCH2 by BCL6 is required to maintain the survival of FL cells. We show that this function is inherited from GC B-cells and is required for development of GCs during the humoral immune response. Finally, we find that BCL6 targeted therapy potently kills FL derived cell lines both in vitro and in vivo, and most importantly, also kills primary human FL patient specimens ex vivo.
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Results

BCL6
regulates specific genes and pathways in FL including NOTCH2.
As a first approach to exploring BCL6 functions in FL we performed ChIP-on-chip to identify direct target genes relevant to this disease. Since no cell lines are available that reflect FL biology in its indolent phase, we performed these studies using CD20 purified B-cells from four independent primary FL patient samples with >80% tumor cell content. ChIP products were co-hybridized with their respective inputs to microarrays representing 25,000 promoters. BCL6 binding sites were identified by random permutation analysis and a peak overlap algorithm (10) . 48.4% of BCL6 binding sites overlapped between the four FL specimens, amounting to a total of 1529 probesets and corresponding to 1712 genes (Supplementary Table S1 ). DNA motif analysis confirmed that BCL6 canonical DNA binding sequence was highly enriched at these BCL6 binding sites (p<1.7 -7 , FIRE algorithm with hypergeometric test (11) , data not shown). To determine whether BCL6 targets in FL lymphoma cells were associated with particular biological functions we queried curated gene signatures relevant to lymphomagenesis (12) . The top 5 gene sets captured by this method using Fisher's exact tests with Benjamini-Hochberg (BH) correction included known direct BCL6 targets from experiments in the Ramos cell line (9), a DLBCL proliferation signature (13), a cell cycle gene set (14) , a Notch induced gene signature (15) and genes repressed by Blimp1 (16) (Fig. 1A, Supplementary Table S2 ). We noted that repression of Notch was not a previously recognized function of BCL6 in the context of Bcell lymphomas.
To distinguish BCL6 target genes likely to contribute to the FL phenotype, we sought to identify those targets most strongly repressed in FL. Analysis of gene expression profiles from 191 FL patients (17) demonstrated that 184 FL BCL6 target genes displayed significant inverse correlation with BCL6 expression, including NOTCH2 (Spearman correlation, p<0.05, Fig. 1B and Supplementary Table S3) .
To determine whether these 184 genes were enriched for any particular pathway category we explored their functional annotation using DAVID (Supplementary Fig. S1A ). This analysis again highlighted NOTCH2 as well as Notch pathway genes involved in cell cycle, apoptosis, cellular morphogenesis, lymphoid organ development or transcription (Supplementary Fig. S1B ). These data suggested that BCL6 might be a repressor of NOTCH2 and NOTCH signaling pathways. In further support of this notion we observed inverse correlation between expression of BCL6 and expression of a curated list (15, 18, 19) of NOTCH cofactors and target genes among which NOTCH2 was the most inversely correlated (Spearman correlation, p<0.05, Fig. 1C to negative control genes (HPRT and COX6B, Fig. 1D and Supplementary Fig. S1C ), similar in magnitude to its enrichment at canonical BCL6 targets like TP53 and BCL6 itself (Fig. S1C) . Moreover, we identified canonical BCL6 DNA binding sites in the regulatory regions of the Notch cofactor genes MAML1, MAML2 and RBP-Jk, all members of the Notch co-activator complex, as well as HES1 a transcriptional repressor and the prototypic Notch pathway transcriptional target (Fig. 1E) . To validate whether these are true BCL6 targets we performed QChIP and confirmed that BCL6 is indeed bound to these loci in two independent FL derived cell lines (Fig. 1F) . Primers used to this analysis are found at Supplementary Table S5 .
Since GC B-cells are the cell of origin of FL, and FL gene expression profiles reflect GC B-cell transcriptional programming we wondered if BCL6 could bind to the Notch2 locus in this setting as well.
Binding of BCL6 to the promoters of NOTCH2, MAML2 and RBP-Jk was confirmed by performing QChIP in independent primary human GC B-cells (Supplementary Fig. S1D ). In addition to FL, GC Bcells give rise to DLBCLs. To determine whether BCL6 could bind and regulate Notch2 and related genes in DLBCLs we used BCL6 ChIp-on chip data performed and analyzed on the same platform as the FLs (10) . Among BCL6 target genes in DLBCL cells the Notch induced gene signature was not significantly enriched (Supplementary Table S6 , S7 and S8) although other gene sets overrepresented in FL BCL6 target genes were also enriched in DLBCL ( Supplementary Fig. S1E and Supplementary Table S6 ). Analysis of gene expression profiles from 71 DLBCL patient samples (20) showed that 245 DLBCL BCL6 target genes displayed significant inverse correlation with BCL6 expression (Spearman correlation, p<0.05, Supplementary Table S7) . Nonetheless, analysis of the curated list of NOTCH cofactors and target genes from Figure 1C indicated that NOTCH2 and other Notch pathway partners were inversely correlated (Spearman correlation, p<0.05, Supplementary Fig.   S1G and Supplementary Table S8) . Furthermore, less than 15% of the genes found in DLBCL subset were shared with the ones found on FL subset (Spearman correlation, p<0.05, Supplementary Table   S9 ). Altogether these results point to NOTCH2 and its cofactors as bona fide BCL6 target genes with potential relevance to the phenotype of FL tumors as well as formation of GCs during the humoral immune response. Although repression of Notch pathway is not as strongly linked with DLBCL, it is evident that BCL6 represses NOTCH2 in this disease subtype as well.
BCL6 and NOTCH2 are inversely correlated in GC B-cells.
Upregulation of BCL6 is required for mature follicular B-cells to differentiate into GC B-cells during the humoral immune response. In contrast NOTCH2 plays a critical role in marginal zone differentiation, which is an alternative cell fate for follicular B-cells (21 Fig. S2A ). We then measured the relative transcript abundance of NOTCH2, MAML1 and MAML2 as well as BCL6 by QPCR ( Fig. 2A) . While BCL6 was upregulated in GC B-cells, NOTCH2, MAML1 and MAML2 (but not RBP-Jk) were concordantly downregulated ( Fig. 2A) Fig. S2B ). During the GC reaction B-cells first become proliferative centroblasts (CB) and then become centrocytes (CC) as they interact with T cells in the GC light zone. We analyzed gene expression in these cell types using RNAseq, and again observed inverse correlation between BCL6 and NOTCH2 in both CB and CC (Figs.
2C-D).
In order to determine whether these changes in gene expression are linked to GC activation signals, we purified human and murine mature B-cells, independently co-cultured them with stromal cells (OP9)
and exposed them to IL4 and IL21 (23, 24) . Murine mature B-cell purity was confirmed by CD45/B220 + staining by flow cytometry (Supplementary Fig. S2C ). In both human and murine cells we observed significant BCL6 upregulation (p<0.0001; p=0.0004 human and murine cells respectively) associated with downregulation of NOTCH2 (p=0.0136; p=0.044) and MAML2 (p=0.0029; p=0.0255), although expression of MAML1 (p=0.1069; p=0.0609) and RBP-Jk (p=0.0784; p=0.1841) was more variable (Fig. 2E-F) . These data suggest that BCL6 repression of NOTCH2 is an integral feature of normal GC B-cell activation and may be critical to specifying the GC phenotype in opposition to marginal zone differentiation.
NOTCH2 expression impairs GC formation.
Given that BCL6 is required for development of GC formation and directly represses NOTCH2, we wondered whether expression of an active form of NOTCH2 (intracellular domain, ICN2) in GC B-cells might disrupt GC formation. To address this question we studied GC formation in a mouse strain engineered to contain an ICN2-IRES-YFP (ICN2) cassette with a loxP flanked start site knocked-in to the ROSA26 locus (25) . These mice were crossed with a tamoxifen inducible ROSA26-Cre-ER T2 strain or in ROSA26-WT control mice. GC formation was induced by immunization with the T-cell dependent antigen NP 65 -CGG. ICN2 expression was induced the following day by tamoxifen injection. Animals
Research. were sacrificed 14 days later and spleens resected for analysis (Supplementary Fig. S3A ). Paraffinembedded spleen sections from WT and ICN2 mice were stained for the GC specific marker PNA (peanut agglutinin), or for BCL6 and B220. GCs were defined as clusters of PNA + or BCL6 + /B220 + cells ( Fig. 3A-B Consistent with the reduction in GCs (which contain cells that proliferate and undergo apoptosis) there was also reduction in the abundance of proliferating cell clusters as shown by PCNA and Ki67 immunohistochemistry ( Supplementary Fig. S4C ), as well as, clusters of cells with apoptotic markers caspase 3 and TUNEL in the ICN2 mice ( Supplementary Fig. S4D ). Given the crucial role of ICN2 in driving marginal zone B-cell differentiation we next stained for MZB markers CD21 and CD23. We
observed an increase in MZB cell population in ICN2 conditional mice in detriment to Follicular B (FoB) cell population (mean of 65% +/-1.5% FoB vs. 15% +/-2.6% MZB) compared to WT (mean of 70% +/-3% FoB vs. 10% +/-1.3% MZB, Supplementary Fig. S4E ). In contrast as expected there was no effect on T lymphoid (single-or double-positive populations stained for CD8/CD4; top panel) or myeloid lineages (CD11b/Gr-1; bottom panel, Supplementary Fig. S4F ). Altogether these data indicate that ICN2 expression is incompatible with B-cells forming GCs and that repression of Notch2 is a critical function of BCL6 in enabling the GC phenotype.
BCL6 represses NOTCH2 expression and activity in FL cells. To confirm that BCL6 directly
represses NOTCH2 and related genes we depleted BCL6 from FL derived cell lines using an siRNA that we validated to be specific for BCL6 (27) compared to scrambled control, followed by QPCR assessment of NOTCH2, MAML1, MAML2 and RBP-Jk transcripts (Fig. 4A) . We observed approximately 2-fold derepression of NOTCH2 and variable derepression of the other genes. This magnitude of derepression is similar to that reported for other BCL6 targets (7, 9, 10, 28, 29) . siBCL6 was confirmed to deplete BCL6 protein (Supplementary Fig. S5A ). To further confirm this result using an independent approach we treated the FL cell lines with the specific BCL6 inhibitor RI-BPI, that binds to the BCL6 BTB repression domain to block the transcriptional effects of BCL6 (7). We first validated that we could reproduce the known effect of RI-BPI in blocking the repressor activity of the BCL6 BTB domain in the context of lymphoma cell lines using a BCL6 BTB domain reporter assay ( Supplementary Fig. S5B ). We then measured the effect of RI-BPI on derepressing NOTCH2, MAML1, MAML2 and RBP-Jk as compared to control peptide and observed a similar effect as that seen with siRNA ( Fig. 4B) . There was no induction of NOTCH1, which was expressed at very low levels in these cells (data not shown). Given that NOTCH2 was also inversely correlated with BCL6 in GCB-DLBCL cells we examined the effect of RI-BPI on two such cell lines and observed generally similar degree of derepression of NOTCH2, MAML1 and MAML2 (Supplementary Fig. S5C ). To determine whether upregulation of NOTCH2 was functionally significant we performed Notch reporter assays in the FL-derived cell lines after BCL6 siRNA. BCL6 knockdown resulted in significant induction of Notch reporter activity (p<0.0001 in both cell lines, unpaired two-tailed t test), but did not affect a control reporter (Fig. 4C) . ( Fig. 4D, 4H) . Hence in the in vivo setting NOTCH ligand delivery to lymphoma cells likely comes mostly from the lymph node microenvironment, where NOTCH ligands are known to be expressed (32), whereupon FLs or mature B-cells are then competent to cleave NOTCH2. Indeed we observed that co-culture of FL cells with a stromal cell line engineered to express DLL1 but not the same cell line without DLL1 reproducibly induced apoptosis, consistent with NOTCH2 signaling being deleterious to these cells (Fig. 4I) .
BCL6 maintains the survival of FL cells in a NOTCH2-dependent manner.
To determine whether BCL6 repression of NOTCH2 was important to its actions in FL cells we first wished to establish whether FL cells are biologically dependent on BCL6. We therefore exposed DoHH2, Sc-1, and WSU-DLCL2 FL-derived cell lines to increasing concentrations of RI-BPI and measured cell viability using a fluorometric resazurin reduction method. DoHH2 and Sc-1 cells displayed a GI 50 of 11.7 μM and 15.2 μM respectively, which is comparable to the GI 50 of BCL6-dependent DLBCL cells (7), whereas WSU-DLCL2 cells were more resistant (Fig. 5A) . Similar to the case of DLBCL (7, 9) , not all FL cells were responsive to RI-BPI, but the ones that were sensitive underwent apoptosis, as shown in caspase 3/7 cleavage assays and annexin V/7AAD flow cytometry ( Fig. 5B and Supplementary Fig. S6A ). To determine whether NOTCH2 repression contributes to the effect of BCL6 in maintaining survival of FL cells we attempted to rescue our panel of BCL6-dependent FL and GCB-DLBCL lymphoma cell lines (DoHH2, Sc-1, SU-DHL-4 and OCI-Ly1) from the effects of BCL6 depletion by preventing NOTCH2 upregulation using an siRNA approach. We verified knockdown of both transcripts (BCL6 and NOTCH2) in each cell line, using two independent siRNA for both BCL6 and NOTCH2 (Supplementary Fig. S6B ). BCL6 knockdown resulted in a ~30-60% loss of viability in all four cell lines at 48h whereas NOTCH2 siRNA alone did not affect cell viability ( Fig. 5C and Supplementary Fig. S6C) . Notably, concordant knockdown of NOTCH2 prevented its upregulation in response to BCL6 siRNA and significantly rescued all of four cell lines from BCL6 siRNA induced loss of viability. We used two independent siRNA sequences for BCL6 and NOTCH2. The rescue of siBCL6-1 sequence by both siNOTCH2 RNA sequences is shown in Figure 5C and the rescue of siBCL6-2 in Supplementary Figure S6C . In contrast the viability of the BCL6 independent t(14;18) lymphoma cell line OCI-Ly8 (8) was not affected by BCL6 or NOTCH2 siRNA, even though they manifested a similar degree of knockdown ( Supplementary Fig. S6D-E) . NOTCH2 siRNA also at least partially rescued FL cells from loss of viability induced by the BCL6 inhibitor RI-BPI (Fig. 5D and data not shown). In a reciprocal experiment, to determine whether induction of Notch2 was sufficient to suppress the growth of FL cells downstream of BCL6 inhibition, we transduced DoHH2 and Sc-1 cells with a retrovirus expressing ICN2 and GFP, or GFP alone. We measured the relative depletion of GFP positive cells from the total population of cells by flow cytometry over the course of ten days. NOTCH2 expression was clearly growth suppressive and sufficient to inhibit FL cells since 95% of ICN2-GFP DoHH2 cells were depleted by ten days, as were 75% of ICN2-GFP Sc-1 cells (Supplementary Fig.   S6F ). Finally, to confirm the importance of NOTCH2 pathway suppression by BCL6 in FL cells, we exposed lymphoma cells to the NOTCH2 antagonist antibody NRR2, after confirming its specificity of action in vivo against Notch2 but not Notch1, consistent with previous reports (Supplementary Figure   7) (33,34). NRR2, but not control antibody could also rescue DoHH2 and SU-DHL-4 cells from cell death induced by RI-BPI to variable degrees (Fig. 5E) . Repression of NOTCH2 is thus a critical downstream mechanism of action of BCL6, required for its ability to maintain the survival of follicular lymphoma cells.
BCL6 inhibitors suppress FL xenografts in vivo and primary human FLs ex vivo. FL cell lines
may not necessarily accurately represent the biology of primary indolent FL in human patients at the time of diagnosis. We obtained a set of seventeen diagnostic primary human FL specimens from patients with non-transformed disease, made single cell suspensions, exposed them to RI-BPI or vehicle ex vivo for 48 hours and then assessed for viability. Immunohistochemistry analysis indicated that 10 patients were clearly BCL6 positive and 7 were borderline positive to negative for BCL6 (data not shown). All 17 samples were exposed to 10 μM RI-BPI or vehicle. While the BCL6 negative/low FLs were resistant to BCL6 inhibitors, 9 out of 10 of the BCL6 positive FLs responded with a 20 to 70% loss of viability (Fig. 6A) . Consistent with the actions of BCL6 in normal GC B-cells and FL cell lines, we observed that in primary human FLs, RI-BPI induced derepression of NOTCH2, as well as induction of the NOTCH2 targets HES1 and HES6 (Fig. 6B) . Moreover, we also observed reexpression of ATF5, APOL6, CCR6, and HOXA13, all of which are direct BCL6 targets inversely correlated with BCL6 expression in FL patients (Fig. 1B and Supplementary Table S3) , and of STAT3, a positive control BCL6 target, but not of HPRT, which is a negative control ( Supplementary   Fig. S8A ). (Fisher exact test p=0.04, Fig. 6C ). Immunohistochemical analysis of these tumors showed an increase in apoptosis in the RI-BPI treated tumors by TUNEL assays from 7% to 12% in DoHH2 (p<0.001, Fisher exact test), and from 10 to 18% (p<0.001, Fisher exact test) in Sc-1 tumors respectively. Analysis of these same tumors by Caspase 3 yielded similar results, from 6% to 22% in DoHH2 (p< 0.0001, Fisher exact test), and from 11 to 21% (p< 0.0001, Fisher exact test) in Sc-1 ( Fig. 6D and Supplementary Fig. S8B-D) . Examination of mRNA extracted from tumor xenografts revealed upregulation of NOTCH2, MAML1, MAML2 and HES1 (p=0.0086, p=0.0011, p=0.0929, and p=0.0079 respectively, Mann-Whitney test) in RI-BPI treated mice vs. vehicle (Fig. 6E) . BCL6 is thus a bona fide therapeutic target in FL at least in part through its repression of NOTCH2, which we show is a growth suppressor in FL.
Discussion
The role of BCL6 in FL has not been previously explored, in part because of considerations such as i) the indolent phenotype of FL distinct from the more aggressive DLBCLs typically associated with BCL6, ii) the frequent t(14:18) translocation focused attention on BCL2, and iii) BCL6 is not often translocated in FL (5). However, our previous work indicated that DLBCL cells are dependent on BCL6 regardless of whether its locus is affected by mutations (7, 8) . Therefore analysis of BCL6 in this disease seemed warranted (35,36). Analysis of the BCL6 cistrome in primary FL specimens suggested new mechanisms of action for BCL6 not previously gleaned from studies in DLBCL.
In particular we focused on BCL6 repression of NOTCH2, a growth suppressor of pre-B leukemia cells and Hodgkin lymphoma cells (37). BCL6 was bound to NOTCH target genes in FL and NOTCH2 levels were inversely correlated with BCL6 in FL. We find that BCL6 is a direct repressor of NOTCH2, Finally, we show that BCL6 is a bona fide therapeutic target in FL, and not just a passenger marker. This was confirmed using two different loss-of-function strategies (siRNA and RI-BPI) and was relevant not only to cell lines but also to primary human BCL6-positive FLs. BCL6 inhibitors also induced NOTCH2 and suppressed the growth of FL xenografts, suggesting that cell autonomous inhibition of an FL survival pathway is able to suppress FL tumor growth in vivo. This is an example of "non-oncogene" dependence, in that even though the BCL6 locus is not usually mutated in FL, cells that express it are biologically dependent on its continued presence to maintain their survival. Since RI-BPI blocks only the BTB domain lateral groove and does not affect other BCL6 functions, FL survival is clearly dependent on BCL6 recruitment of corepressors to the BCL6 BTB domain (7) . The presented data suggest that BCL6 targeted therapy could be a useful approach for treatment of FLs.
Importantly, since RI-BPI only affects certain BCL6 functions (46) it does not induce toxicity or inflammation in animals even when administered long-term and so is suitable as a therapeutic agent for diseases that might require chronic dosing (7) . Likewise animals engineered to express a BCL6 mutant that mimics the loss of function induced by RI-BPI live normal healthy lives (47). The data expand the spectrum of patients who are candidates for RI-BPI or other BCL6 inhibitor clinical trials and offer a potential approach for more effectively eradicating these incurable tumors. 
Materials and Methods
Gene expression microarray data and RNA-seq. Publically available gene expression microarray data were obtained from 191 primary FLs (9) . Data processing and normalization were performed as previously described (9) . For the examination of available gene expression profiles obtained from five independent sets of NB and GC B-cells, data publicly available was obtained from GC B-cell array accession number: GSE2350 (22) . BCL6 ChIP-on-chip data has been submitted to GEO GSE29165. suspensions from lymph node biopsies were obtained by physical disruption of tissues (using scalpels and cell strainers), followed by cell density gradient separation (Fico/Lite LymphoH; Atlanta Biologicals, Norcross, GA). Cell number and viability were determined by trypan blue dye exclusion, and cells were cultivated in medium containing 80% RPMI and 20% human serum supplemented with antibiotics, L-glutamine 4 mM and HEPES 10 mM. Cells were exposed in duplicates to control and RI-BPI at indicated concentrations for 48 h. Viability was determined as detailed above. The BCL6 protein status was determined in paraffin-embedded samples by immunohistochemistry using anti-BCL6
(Dako North America, Carpinteria, CA).
Mice xenotransplant studies. All animal procedures followed NIH protocols and were approved by the Animal Institute Committee of the Weill Cornell Medical College. Six to eight-week old male SCID mice were purchased from the National Cancer Institute (NCI) and housed in a clean environment.
Mice were subcutaneously injected in the left flank with low-passage 10 7 human lymphoma cells (DoHH2 and Sc-1). Tumor volume was monitored every other day using electronic digital calipers in two dimensions. Tumor volume was calculated using the formula: Tumor Volume (mm CompuSyn software package (Biosoft, Cambridge, UK) was used to plot dose-effect curves and determine the drug concentration that inhibits the growth of cell lines by 50% compared to control (GI 50 ). The linear correlation coefficient was higher than 0.90 for each curve in the median-effect plot.
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